Outset Keeps $125M-$130M Goal Alive as HCA's $40M Tablo Refresh Turns Into an August Smell Test

HCA's $40M Tablo Refresh Supports the Story, but August Earnings Do the Proving

HCA's approximately $40 million Tablo refresh is the kind of contract that looks strong on paper: a committed capital purchase from 2026 through 2028, plus a console and consumables framework for potential growth beyond current sites. That matters, but it is still forward-looking. Investors already know Tablo has real-world use in dialysis insourcing; now they need evidence that the refresh starts showing up in reported results.

That is why August matters. Outset reported second-quarter 2026 revenue of $31.6 million, up 1% from a year earlier and 14% sequentially, and it reiterated its full-year revenue guidance of $125 million to $130 million, implying 5% to 9% growth from 2025. That leaves some room for execution. If HCA's rollout begins cleanly and Outset holds that range, confidence in the story should improve. If not, the market may treat the refresh as a positive signal rather than a near-term earnings catalyst.

Tablo's Operating Case Depends on Adoption and Recurring Use

The core question is not whether Outset has a real product. It is whether Tablo can keep moving from contract wins and installations into steady, measurable growth. Management has signaled that much of the 2026 growth should show up in the back half of the year, making Q3 and Q4 the first real test.

The reference base and training advantage matter

Tablo's strongest selling point is that it makes insourcing dialysis easier to adopt and run. Outset says the system is trusted by more than 1,000 U.S. healthcare facilities, which gives the company a credible reference base in hospital sales. Hospitals are also more likely to act when they can point to existing users.

Adoption friction is the next hurdle. Outset says Nurses can be trained on Tablo in less than 4 hours, a detail that matters to operators. That claim also fits with management's note that the company completed its highest number of successful new-site implementations in several years. More clean launches should help turn interest into live sites faster.

Console sales matter, but consumable traction is the durability test

The business model is straightforward: a console sale gets the system on site, and ongoing use is where the model can get healthier. HCA's amendment is not just a committed capital purchase; it also includes a console and consumables framework for growth beyond current sites.

That is why the mix matters. In Q2, console revenue rose 6%, but consumable revenue declined 12%. Bears can use that gap to question the recurring piece. Bulls can argue that one quarter is not decisive when implementations are accelerating and the back-half rollout is still ahead. The next few reports should show whether usage is catching up to hardware placement.

What August Needs to Show

August is the first real read on whether Outset can convert a strong contract headline into earned growth. The company already has scale and a relatively low-friction setup: Tablo is trusted by more than 1,000 U.S. healthcare facilities, and Nurses can be trained on Tablo in less than 4 hours. What investors need now is evidence that that base is translating into the right revenue mix.

Bull-case signals to watch

If the bull case is holding, the quarter should show broader strength rather than narrow headline support. Key positive signals would include:

• Outset holding its full-year revenue guidance of $125 million to $130 million.
• Continued progress tied to the highest number of successful new-site implementations in several years.
• Console revenue rose 6% alongside less weakness in consumables.

That last point matters most. Consoles open the door; recurring use is what keeps the business durable.

Why the stock could still stumble

Bears do not need to doubt the product to make the case. Their argument is simpler: a future contract and current earnings are not the same thing. If HCA remains mostly a pipeline item for now and product revenue is still soft, the market may view the refresh as good signage rather than strong near-term proof.

Margins also deserve close attention. Outset said Non-GAAP gross margin improved to 42.2%. If management links that improvement to cost reductions, service efficiencies, and better execution, the operating story gets stronger. If not, investors may question whether the margin gain reflects the right mix of drivers.

The simple takeaway

For August, the test is straightforward: steady unit growth plus improving commercial execution. If both show up, HCA starts to look like real proof. If not, Outset remains a good story that still needs harder numbers.